Product image of Lenalidomide Sandoz (Lenalidomide) supplied by GNH India

Lenalidomide Sandoz

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Sandoz (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Sandoz, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is employed in the treatment of multiple myeloma and myelodysplastic syndromes, primarily in adult patients. The medication works by modulating immune function and inhibiting tumor blood vessel formation.

GNH India supplies Lenalidomide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with established quality assurance processes and regulatory compliance across multiple regions.

Manufacturer / TM Owner

Sandoz Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders.

  • Multiple myeloma: improves progression‑free survival and overall response rates in adult patients.
  • Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission.
  • Mantle cell lymphoma (in combination therapy): contributes to tumor control in adult patients.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This results in modulation of cytokine production, enhanced T‑cell and NK‑cell activity, and inhibition of angiogenesis, collectively exerting antineoplastic effects.

Side Effects

Common Side Effects

  • Fatigue: persistent tiredness reported by many patients.
  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Thrombocytopenia: lowered platelet levels leading to easy bruising.
  • Diarrhea: mild to moderate gastrointestinal upset.
  • Rash: skin irritation or erythema.
  • Nausea: occasional upset stomach.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Severe neutropenia with infection: heightened susceptibility to serious infections.
  • Secondary primary malignancies: emergence of new cancers.
  • Hepatic toxicity: elevated liver enzymes or liver injury.
  • Severe skin reactions (e.g., Stevens‑Johnson syndrome): extensive skin detachment.
  • Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Precautions & Warnings

Lenalidomide requires careful monitoring and specific safety measures.

  • Pregnancy: contraindicated (Category X); avoid use in pregnant women.
  • Thrombosis risk: assess and consider prophylaxis in patients with additional risk factors.
  • Hematologic monitoring: perform regular CBC to detect cytopenias.
  • Renal impairment: adjust dosing and monitor renal function.
  • Drug interactions: avoid concomitant use with strong CYP inducers without supervision.
  • Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Lenalidomide may interact with several medicines; clinicians should review patient regimens.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure.
  • Anticoagulants (e.g., warfarin): increased bleeding risk.
  • Live vaccines: heightened infection risk due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • P‑glycoprotein inhibitors (e.g., verapamil): may increase plasma levels.
  • H2 antagonists (e.g., ranitidine): may affect absorption.
  • Concomitant chemotherapy agents (e.g., melphalan): additive myelosuppression.

Frequently Asked Questions

Lenalidomide Sandoz is indicated for the treatment of multiple myeloma and for myelodysplastic syndromes that carry a del(5q) cytogenetic abnormality. In these settings it helps control disease progression and can reduce the need for blood transfusions.

Lenalidomide binds to the cereblon protein within the CRL4‑E3 ubiquitin ligase complex, leading to the targeted degradation of transcription factors Ikaros and Aiolos. This action modifies immune cell activity, suppresses angiogenesis, and ultimately exerts antitumor effects.

The specific dose of Lenalidomide Sandoz is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Only a qualified healthcare professional should set the dosing regimen.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended for breastfeeding mothers because it may be excreted in breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory imide drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens and provides benefits in disease control and progression‑free survival, especially in patients who have relapsed or are receiving maintenance therapy.

Lenalidomide Sandoz should be stored at ambient temperature, below 25 °C, in its original packaging. The container protects the tablets from moisture and light, helping to maintain product stability throughout its shelf life.

The medication is taken orally, usually with water. Patients should follow the prescriber’s instructions regarding timing (e.g., with or without food) and any required fasting periods to ensure optimal absorption.

Serious risks include venous thromboembolism, severe neutropenia leading to infection, secondary primary malignancies, hepatic toxicity, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of these events.

Lenalidomide Sandoz should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled severe infections. Clinicians must also evaluate renal function and avoid use in patients for whom the risk‑benefit profile is unfavorable.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT